首页> 美国卫生研究院文献>Protein Science : A Publication of the Protein Society >N-linked glycosylation of dipeptidyl peptidase IV (CD26): Effects on enzyme activity homodimer formation and adenosine deaminase binding
【2h】

N-linked glycosylation of dipeptidyl peptidase IV (CD26): Effects on enzyme activity homodimer formation and adenosine deaminase binding

机译:N-联二肽基肽酶IV(CD26)的糖基化:对酶活性同型二聚体形成和腺苷脱氨酶结合的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The type II transmembrane serine protease dipeptidyl peptidase IV (DPPIV), also known as CD26 or adenosine deaminase binding protein, is a major regulator of various physiological processes, including immune, inflammatory, nervous, and endocrine functions. It has been generally accepted that glycosylation of DPPIV and of other transmembrane dipeptidyl peptidases is a prerequisite for enzyme activity and correct protein folding. Crystallographic studies on DPPIV reveal clear N-linked glycosylation of nine Asn residues in DPPIV. However, the importance of each glycosylation site on physiologically relevant reactions such as dipeptide cleavage, dimer formation, and adenosine deaminase (ADA) binding remains obscure. Individual Asn→Ala point mutants were introduced at the nine glycosylation sites in the extracellular domain of DPPIV (residues 39–766). Crystallographic and biochemical data demonstrate that N-linked glycosylation of DPPIV does not contribute significantly to its peptidase activity. The kinetic parameters of dipeptidyl peptidase cleavage of wild-type DPPIV and the N-glycosylation site mutants were determined by using Ala-Pro-AFC and Gly-Pro-pNA as substrates and varied by <50%. DPPIV is active as a homodimer. Size-exclusion chromatographic analysis showed that the glycosylation site mutants do not affect dimerization. ADA binds to the highly glycosylated β-propeller domain of DPPIV, but the impact of glycosylation on binding had not previously been determined. Our studies indicate that glycosylation of DPPIV is not required for ADA binding. Taken together, these data indicate that in contrast to the generally accepted view, glycosylation of DPPIV is not a prerequisite for catalysis, dimerization, or ADA binding.
机译:II型跨膜丝氨酸蛋白酶二肽肽酶IV(DPPIV),也称为CD26或腺苷脱氨酶结合蛋白,是各种生理过程的主要调节剂,包括免疫,炎症,神经和内分泌功能。已经普遍接受的是,DPPIV和其他跨膜二肽基肽酶的糖基化是酶活性和正确的蛋白质折叠的先决条件。 DPPIV的晶体学研究表明DPPIV中9个Asn残基具有清晰的N-联糖基化作用。但是,每个糖基化位点在生理相关反应(如二肽裂解,二聚体形成和腺苷脱氨酶(ADA)结合)上的重要性仍然不清楚。单个Asn→Ala点突变体被引入DPPIV胞外域的9个糖基化位点(残基39–766)。晶体学和生化数据表明,DPPIV的N-联糖基化对其肽酶活性没有明显贡献。以Ala-Pro-AFC和Gly-Pro-pNA为底物,测定野生型DPPIV和N-糖基化位点突变体的二肽基肽酶裂解动力学参数。 DPPIV作为同型二聚体具有活性。尺寸排阻色谱分析表明,糖基化位点突变体不影响二聚化。 ADA与DPPIV的高度糖基化的β-螺旋结构域结合,但以前尚未确定糖基化对结合的影响。我们的研究表明,ADAP不需要DPPIV的糖基化。总体而言,这些数据表明,与普遍接受的观点相反,DPPIV的糖基化并不是催化,二聚化或ADA结合的先决条件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号